EUVIMEDEUVIMED entdecken
Leserbrief

Letter to the editor regarding “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”

Fleur L Meulmeester iD, Camiel J M Marijnissen iD, Jacob K Sont iD

International Forum of Allergy & Rhinology · 2026-11 · 16 (11) · 1383-1384

DOI: 10.1002/alr.70291 ↗

Kurz gefasst

Leserbrief in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 14.10.2026. Verfasst von Fleur L Meulmeester und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Data Sciences, Caecilia Institute for Population Health and Data Sciences, Leiden University Medical Center, Leiden, The Net…. Die Arbeit nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Biomedical Data Sciences, Caecilia Institute for Population Health and Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Fleur L Meulmeester, Camiel J M Marijnissen, Jacob K Sont

Zitieren

APA

Meulmeester, F. L., Marijnissen, C. J. M., & Sont, J. K. (2026). Letter to the editor regarding “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”. International Forum of Allergy & Rhinology, 16(11), 1383-1384. https://doi.org/10.1002/alr.70291

Vancouver

Meulmeester FL, Marijnissen CJM, Sont JK. Letter to the editor regarding “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”. International Forum of Allergy & Rhinology. 2026;16(11):1383-1384. doi:10.1002/alr.70291

BibTeX
@article{Meulmeester2026,
  author = {Meulmeester, Fleur L and Marijnissen, Camiel J M and Sont, Jacob K},
  title = {Letter to the editor regarding “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”},
  journal = {International Forum of Allergy & Rhinology},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {1383--1384},
  doi = {10.1002/alr.70291}
}
Kostenlos starten →